Cetirizine-Vertex, 10 mg 10 pcs

Pharmgroup:

anti-allergic agent – H1-histamine receptor blocker. Pharmacological action: A competitive histamine antagonist, a metabolite of hydroxyzine, blocks H1-histamine receptors. Prevents the development and facilitates the course of allergic reactions, has antipruritic and antiexudative action.

It affects the early stage of allergic reactions, limits the release of inflammatory mediators at the “late” stage of allergic reaction, reduces migration of eosinophils, neutrophils and basophils. It reduces capillary permeability, prevents the development of tissue edema, relieves smooth muscle spasm.

Limits the skin reaction to the introduction of histamine, specific allergens, as well as to cooling (with cold urticaria). Reduces histamine-induced bronchoconstriction in mild bronchial asthma. Practically has no anticholinergic and antiserotonin action.

In therapeutic doses practically does not cause sedative effect. The beginning of the effect after a single dose of 10 mg of cetirizine is 20 minutes (in 50% of patients) and after 60 minutes (in 95% of patients) and lasts more than 24 hours. During a course of treatment, tolerance to the antihistamine effect of cetirizine does not develop. After discontinuation of treatment the action lasts up to 3 days.

Indications

seasonal and year-round allergic rhinitis and conjunctivitis (itching, sneezing, rhinorrhea, lacrimation, conjunctival hyperemia); urticaria (including chronic idiopathic urticaria); hay fever (hay fever); itching; angioedema (Quincke’s edema); itchy allergic dermatoses.

Pharmacological effect

Pharmaceutical group:

antiallergic agent – H1-histamine receptor blocker. Pharmaceutical action: Competitive histamine antagonist, hydroxyzine metabolite, blocks H1-histamine receptors. Prevents the development and facilitates the course of allergic reactions, has antipruritic and antiexudative effects.

Affects the early stage of allergic reactions, limits the release of inflammatory mediators at the “late” stage of the allergic reaction, reduces the migration of eosinophils, neutrophils and basophils. Reduces capillary permeability, prevents the development of tissue edema, relieves spasm of smooth muscles.

Eliminates skin reactions to the introduction of histamine, specific allergens, as well as to cooling (with cold urticaria). Reduces histamine-induced bronchoconstriction in mild bronchial asthma. It has virtually no anticholinergic and antiserotonin effects.

In therapeutic doses it practically does not cause a sedative effect. The onset of effect after a single dose of 10 mg of cetirizine is 20 minutes (in 50% of patients) and after 60 minutes (in 95% of patients), lasting more than 24 hours. During a course of treatment, tolerance to the antihistamine effect of cetirizine does not develop. After stopping treatment, the effect lasts up to 3 days.

Special instructions

If the dose is exceeded 10 mg/day, the ability to react quickly may deteriorate.

In recommended doses, it does not enhance the effect of ethanol (at a concentration of no more than 0.8 g/l), however, it is recommended to refrain from using it during treatment.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Cetirizine

Composition

Film-coated tablets.

1 film-coated tablet contains:

active substance:

cetirizine dihydrochloride 10 mg;

excipients:

microcrystalline cellulose,

lactose monohydrate,

crospovidone,

magnesium stearate,

colloidal silicon dioxide.

shell composition:

[hypromellose, talc, titanium dioxide, macrogol 4000] or [dry white film shell containing hypromellose, talc, titanium dioxide, macrogol 4000].

Pregnancy

Contraindicated during pregnancy and lactation.

Contraindications

decreased renal function (creatinine clearance 30-49 ml/min); chronic renal failure; children under 6 years of age; pregnancy; lactation period; hypersensitivity to cetirizine, other components of the drug, hydroxyzine.

With caution: old age (possibly decreased glomerular filtration rate).

Side Effects

Drowsiness, dry mouth; rarely – headache, dizziness, migraine, gastrointestinal discomfort, allergic reactions (angioedema, rash, urticaria, itching).

Interaction

No pharmacokinetic interactions were detected with pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, diazepam and glipizide.

Co-administration with theophylline (400 mg/day) leads to a decrease in the total clearance of cetirizine (theophylline kinetics does not change). Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

Overdose

Symptoms (occur when taking a single dose of 50 mg) – dryness of the oral mucosa, drowsiness, urinary retention, constipation, anxiety, increased irritability.

Treatment: gastric lavage, prescription of symptomatic drugs. There is no specific antidote. Hemodialysis is ineffective.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

Vertex, Russia